Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Case Study – Initial ADMET Screen

By Drug Discovery Trends Editor | June 24, 2010

Situation: The client had compounds with novel structures for use in the treatment of respiratory disorders. The first batch of analogs had been synthesized and was in the process of going through in vivo testing. Potential ADMET problems to be addressed by the medicinal chemistry program needed to be identified.


Nothing was known about the ADMET properties of the compounds. No in vitro assay for efficacy was available. Preliminary in vivo results did not match with predictions of efficacy based on structure.


The cost and duration of in vivo testing required careful pre-selection of compounds. It was necessary to identify the ADMET issues associated with each compound and to come up with a paradigm to apply to the compounds to take forward to the animal efficacy and pharmacokinetics studies.


Client scientists consulted with Apredica on the chemistry of the compounds. Apredica scientists gave suggestions regarding structural flaws that may be causing inconsistencies in in vivo results. To test this hypothesis, Apredica conducted a battery of assays to determine drug-drug interactions, stability, solubility, Caco-2 permeability and cytotoxicity of the compounds.


Results: Apredica identified the major ADMET liability: fast plasma metabolism of the compounds. Following discussions of the data, Apredica and client scientists designed and implemented custom experiments to confirm the mechanism of liability.


Apredica then designed custom assays to screen compounds prior to in vivo testing and ranked the compounds according to their ADMET liability.


The client implemented the strategy, which resulted in a rational funnel from early in vitro tests to in vivo efficacy. The fewer compounds selected for in vivo efficacy had significantly better properties that did not obscure efficacy results. Chemists had clear structure activity relationship (SAR). A pre-clinical candidate and a backup series were selected a few months after selecting the strategy. With the data provided by Apredica, the client was able to prioritize compounds for animal studies.


Apredica


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE